Skip to main content
. 2020 Jan 10;11:220. doi: 10.1038/s41467-019-14046-9

Fig. 7. Vaccination with Arf1-ablated cells protects animals from developing tumors.

Fig. 7

a Experimental setup. B16-F10 cells that were transfected with sh-Arf1 or sh-Scram or treated with the Arf1 inhibitor GCA or DMSO were injected into the left side of C57BL/6J mice, and the mice were then re-challenged 1 week later with untreated B16-F10 cells on the right side. b, c Tumor sizes from B16-F10 cells treated with the indicated reagents and transplanted into C57BL/6J mice. Scale bars: 2 cm. d, e Tumor-free curves of B16-F10 cells treated with the indicated reagents and transplanted into C57BL/6J mice. f, g Tumor-volume curves of B16-F10 cells treated with the indicated reagents and transplanted into C57BL/6J mice. h Intestinal tumor number of mice with the indicated genotypes after treatment with isotype or an anti-PD1 antibody. i Tumor numbers of MYC-ON mice treated with the indicated reagents. j Tumor weights of MYC-ON mice treated with the indicated reagents. k Survival curves of MYC-ON mice treated with the indicated reagents. l Correlation analysis for the Arf1 expression level versus IFNγ signature from a human cancer database. m Proposed model depicting how Arf1 knockdown promotes metabolic stress, the induction of DAMPs, and immune cell infiltration and activation to attack tumors (b–g: n = 10; h: n = 10; i: n = 8; j: isotype group, n = 7, anti-PD1 group, n = 8; k: n = 8 mice each group; *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t-test; polled two independent experiments). Data are shown as the mean ± SEM.